Neuroendocrine Tumors Metastatic to the Pancreas Can Mimic Primary Pancreatic Well-Differentiated Neuroendocrine Tumors: Clinical and Pathologic Features in a Multi-Institutional and International Study

Extrapancreatic well-differentiated neuroendocrine tumors (NETs) can metastasize to the pancreas and mimic primary pancreatic NETs (PanNETs). We analyzed 12 patients with pathologically confirmed pancreatic involvement by NET and a documented extrapancreatic primary, comparing their immunophenotype with that of 195 primary PanNETs. The primary site was assigned independently of the immunohistochemical panel under investigation, using clinical and radiologic findings, disease distribution, and comparative morphology. Direct comparison of the primary and pancreatic tumors was possible in 9 cases and demonstrated concordant morphology. Ileal NETs accounted for 9 of 12 cases (75%); the other arose in the lung ( n = 2) and kidney ( n = 1). All 9 ileal metastases expressed serotonin and CDX2, and 8 of 9 expressed SATB2. Compared with primary PanNETs, metastatic NETs more frequently expressed serotonin (11/12 [92%] vs. 20/195 [10%]), SATB2 (9/12 [75%] vs. 14/165 [8%]), and CDX2 (9/12 [75%] vs. 17/190 [9%]). Conversely, ISL1 (2/12 [17%] vs. 139/186 [75%]) and ARX (1/12 [8%] vs. 124/187 [66%]) were more frequently expressed in primary PanNETs (all FDR-adjusted P < 0.001). Because most metastatic tumors were of ileal origin, these associations largely reflect an ileal immunophenotype and should not be interpreted as site-independent estimates of diagnostic performance. Determining tumor origin requires clinical history, imaging, comparative morphology, and targeted immunohistochemistry. Serotonin, SATB2, and CDX2 expression may support an ileal origin, whereas expression of ISL1 and ARX may support a pancreatic origin; no individual marker is definitive.

Authors

Institutions

Publication Details

Journal
Endocrine Pathology
Published
2026-11-19
DOI
https://doi.org/10.1007/s12022-026-09941-z
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neuroendocrine Tumors Metastatic to the Pancreas Can Mimic Primary Pancreatic Well-Differentiated Neuroendocrine Tumors: Clinical and Pathologic Features in a Multi-Institutional and International Study

Ralph H. Hruban, Ayako Ura, Amanda L. Blackford, Kelly J. Lafaro et al.
Endocrine Pathology
Neuroendocrine Tumor Research Advances
article

Neuroendocrine Tumors Metastatic to the Pancreas Can Mimic Primary Pancreatic Well-Differentiated Neuroendocrine Tumors: Clinical and Pathologic Features in a Multi-Institutional and International Study

Ralph H. Hruban, Ayako Ura, Amanda L. Blackford, Kelly J. Lafaro, Richard Andrew Burkhart, Atsuko Kasajima, Carolin Mogler, Christopher R. Shubert, Eric D. Young, Günter Klöppel, William R. Burns, John L. Cameron, Mohammad Salimian, Pedram Argani, Jin He, Tiane Chen
article en

Abstract

Extrapancreatic well-differentiated neuroendocrine tumors (NETs) can metastasize to the pancreas and mimic primary pancreatic NETs (PanNETs). We analyzed 12 patients with pathologically confirmed pancreatic involvement by NET and a documented extrapancreatic primary, comparing their immunophenotype with that of 195 primary PanNETs. The primary site was assigned independently of the immunohistochemical panel under investigation, using clinical and radiologic findings, disease distribution, and comparative morphology. Direct comparison of the primary and pancreatic tumors was possible in 9 cases and demonstrated concordant morphology. Ileal NETs accounted for 9 of 12 cases (75%); the other arose in the lung ( n = 2) and kidney ( n = 1). All 9 ileal metastases expressed serotonin and CDX2, and 8 of 9 expressed SATB2. Compared with primary PanNETs, metastatic NETs more frequently expressed serotonin (11/12 [92%] vs. 20/195 [10%]), SATB2 (9/12 [75%] vs. 14/165 [8%]), and CDX2 (9/12 [75%] vs. 17/190 [9%]). Conversely, ISL1 (2/12 [17%] vs. 139/186 [75%]) and ARX (1/12 [8%] vs. 124/187 [66%]) were more frequently expressed in primary PanNETs (all FDR-adjusted P < 0.001). Because most metastatic tumors were of ileal origin, these associations largely reflect an ileal immunophenotype and should not be interpreted as site-independent estimates of diagnostic performance. Determining tumor origin requires clinical history, imaging, comparative morphology, and targeted immunohistochemistry. Serotonin, SATB2, and CDX2 expression may support an ileal origin, whereas expression of ISL1 and ARX may support a pancreatic origin; no individual marker is definitive.

Endocrine PathologyVol. 37(1)
Johns Hopkins University (US), Johns Hopkins Medicine (US), Sidney Kimmel Comprehensive Cancer Center (US), Technical University of Munich (DE)
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon